Xanax Recalled Nationwide Over Failed Quality Specifications

Apr 18, 2026

Viatris has recalled one lot of Xanax nationwide after the anxiety medication failed dissolution specifications, the FDA announced March 17. The recall affects lot number 8177156, which contains 60 tablets of the 3-milligram extended-release version with an expiration date of February 28, 2027. The tablets may not properly break down and release the drug into the body as intended, potentially causing reduced effectiveness or inconsistent dosing. The FDA classified this as a Class II recall, meaning use may cause temporary or medically reversible health consequences, with remote probability of serious adverse effects.

FDA recall details and affected product specifications

▪The recalled Xanax lot number 8177156 has an expiration date of February 28, 2027.
▪The Xanax recall issued March 17 affects lot number 8177156.
▪The recalled Xanax bottles contain 60 tablets of the 3-milligram extended-release version.
▪Viatris recalled one lot of Xanax nationwide due to failed dissolution specifications.
▪The recalled Xanax tablets may not break down and release the drug into the body as intended.

Health risks and safety classification of the recall

▪The recalled Xanax medication could be less effective or lead to inconsistent dosing.
▪FDA Class II recall classification means use of the product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
▪The Xanax recall has been classified as Class II by the FDA.

Perspective of Viatris

▪Viatris is the pharmaceutical company responsible for manufacturing the recalled Xanax lot number 8177156.

Perspective of Patients prescribed Xanax 3-milligram extended-release tablets

▪Patients with Xanax lot number 8177156 should check their medication bottles to determine if they have the recalled product.
▪Patients taking the recalled Xanax tablets may experience reduced anxiety symptom control due to improper drug dissolution.